tolterodine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2705 124937-51-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tolterodine
  • tolterodine tartrate
  • (+)-Tolterodine
  • (R)-Tolterodine
An ANTIMUSCARINIC AGENT selective for the MUSCARINIC RECEPTORS of the BLADDER that is used in the treatment of URINARY INCONTINENCE and URINARY URGE INCONTINENCE.
  • Molecular weight: 325.50
  • Formula: C22H31NO
  • CLOGP: 5.24
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 1
  • TPSA: 23.47
  • ALOGS: -4.78
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 12 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 24.58 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 25, 1998 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary tract infection 106.58 11.74 276 22101 223744 50359003
Sensitivity to weather change 96.58 11.74 49 22328 5952 50576795
Dry mouth 84.72 11.74 114 22263 56064 50526683
Multiple sclerosis relapse 80.28 11.74 97 22280 42867 50539880
Multiple sclerosis 80.22 11.74 69 22308 20424 50562323
Urinary incontinence 70.31 11.74 74 22303 28134 50554613
Fall 65.46 11.74 307 22070 334625 50248122
Maternal exposure during pregnancy 55.27 11.74 4 22373 159774 50422973
Pollakiuria 53.18 11.74 59 22318 23792 50558955
Systemic lupus erythematosus 50.17 11.74 3 22374 140619 50442128
Antinuclear antibody negative 46.10 11.74 12 22365 204 50582543
Contraindicated product administered 45.57 11.74 6 22371 148952 50433795
Coombs positive haemolytic anaemia 45.17 11.74 13 22364 326 50582421
Bladder disorder 41.46 11.74 31 22346 7512 50575235
Nocturia 40.02 11.74 29 22348 6701 50576046
Herpes simplex reactivation 38.88 11.74 12 22365 385 50582362
Treatment failure 38.79 11.74 7 22370 137630 50445117
Hypertonic bladder 35.60 11.74 20 22357 2980 50579767
Off label use 35.23 11.74 101 22276 474325 50108422
Exposure during pregnancy 34.43 11.74 6 22371 121009 50461738
Cerebrovascular accident 31.68 11.74 103 22274 94577 50488170
Paranoia 31.00 11.74 30 22347 10318 50572429
Stress urinary incontinence 30.73 11.74 16 22361 2049 50580698
Glossodynia 30.23 11.74 7 22370 115562 50467185
Hallucination, auditory 30.09 11.74 30 22347 10698 50572049
Infusion related reaction 29.96 11.74 19 22358 169538 50413209
Drug intolerance 29.53 11.74 32 22345 219072 50363675
Urinary retention 29.05 11.74 46 22331 26144 50556603
Micturition urgency 28.68 11.74 26 22351 8238 50574509
Gastritis haemorrhagic 27.77 11.74 13 22364 1324 50581423
Balance disorder 27.51 11.74 81 22296 70509 50512238
Bladder spasm 26.94 11.74 13 22364 1417 50581330
Gastrooesophageal reflux disease 26.33 11.74 84 22293 76344 50506403
Antiphospholipid syndrome 26.21 11.74 13 22364 1504 50581243
Transient ischaemic attack 25.81 11.74 49 22328 32161 50550586
Hyperlipidaemia 25.59 11.74 35 22342 17455 50565292
Coronary artery disease 24.79 11.74 46 22331 29680 50553067
Depression 24.13 11.74 140 22237 165283 50417464
Wound 22.98 11.74 9 22368 105785 50476962
Dizziness 22.97 11.74 244 22133 346125 50236622
Complex regional pain syndrome 22.87 11.74 13 22364 1980 50580767
Oesophagitis 21.45 11.74 28 22349 13355 50569392
Abdominal discomfort 20.49 11.74 45 22332 231596 50351151
Hypothyroidism 20.38 11.74 46 22331 34079 50548668
Toxicity to various agents 19.02 11.74 41 22336 212458 50370289
Gait disturbance 18.74 11.74 122 22255 149883 50432864
Mental status changes 18.53 11.74 46 22331 36226 50546521
Urge incontinence 18.19 11.74 8 22369 705 50582042
Completed suicide 18.05 11.74 19 22358 131870 50450877
Anxiety disorder 17.79 11.74 14 22363 3659 50579088
Infection 17.53 11.74 31 22346 172923 50409824
Swelling 16.97 11.74 40 22337 200832 50381915
White blood cell count abnormal 16.73 11.74 16 22361 5424 50577323
Secondary progressive multiple sclerosis 16.56 11.74 9 22368 1257 50581490
Iliac artery occlusion 16.36 11.74 5 22372 155 50582592
Barrett's oesophagus 16.09 11.74 7 22370 601 50582146
Constipation 15.82 11.74 138 22239 185570 50397177
Drug hypersensitivity 15.77 11.74 175 22202 250835 50331912
Neutrophil count abnormal 15.55 11.74 11 22366 2448 50580299
Osteonecrosis 15.33 11.74 32 22345 22485 50560262
Confusional state 15.24 11.74 137 22240 185791 50396956
Pericarditis 15.05 11.74 8 22369 78681 50504066
Dysphagia 15.01 11.74 71 22306 77447 50505300
Drug abuse 14.92 11.74 4 22373 59842 50522905
Therapy non-responder 14.85 11.74 53 22324 50969 50531778
Myocardial infarction 14.74 11.74 78 22299 88949 50493798
Incontinence 14.63 11.74 20 22357 9965 50572782
Neutropenia 14.56 11.74 27 22350 147938 50434809
Stomatitis 14.55 11.74 14 22363 101330 50481417
Hepatic enzyme increased 14.49 11.74 24 22353 137356 50445391
Malignant neoplasm progression 14.46 11.74 6 22371 68118 50514629
Peritonitis 14.23 11.74 25 22352 15461 50567286
Pain 14.19 11.74 176 22201 578727 50004020
Neurogenic bladder 14.07 11.74 11 22366 2846 50579901
Aphonia 13.99 11.74 18 22359 8460 50574287
Product complaint 13.92 11.74 21 22356 11445 50571302
Varicose ulceration 13.89 11.74 6 22371 506 50582241
Haemoglobin abnormal 13.61 11.74 13 22364 4399 50578348
Cardiac failure congestive 13.33 11.74 73 22304 84309 50498438
Body temperature fluctuation 12.88 11.74 9 22368 1964 50580783
Visual impairment 12.83 11.74 62 22315 68213 50514534
Cystitis 12.72 11.74 46 22331 44518 50538229
Increased appetite 12.64 11.74 17 22360 8344 50574403
Colitis ischaemic 12.42 11.74 18 22359 9465 50573282
Febrile neutropenia 12.34 11.74 15 22362 97652 50485095
Pathological fracture 12.20 11.74 16 22361 7666 50575081
Haemoglobin 11.90 11.74 4 22373 169 50582578
Chronic obstructive pulmonary disease 11.88 11.74 51 22326 53384 50529363

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seronegative arthritis 66.19 14.84 19 6935 905 29566668
Lipoma 58.00 14.84 19 6935 1412 29566161
Dry mouth 53.71 14.84 43 6911 21741 29545832
Fall 45.89 14.84 117 6837 177061 29390512
Urinary incontinence 41.62 14.84 33 6921 16448 29551125
Inflammatory marker increased 40.65 14.84 19 6935 3648 29563925
Prostatic specific antigen increased 40.24 14.84 29 6925 12535 29555038
Pollakiuria 38.76 14.84 32 6922 16884 29550689
Urinary retention 37.94 14.84 42 6912 31856 29535717
Balance disorder 36.91 14.84 44 6910 36126 29531447
Musculoskeletal discomfort 33.44 14.84 20 6934 6321 29561252
Micturition urgency 31.74 14.84 18 6936 5155 29562418
Multiple sclerosis 30.55 14.84 18 6936 5536 29562037
Confusional state 21.07 14.84 72 6882 127805 29439768
Urinary tract infection 20.99 14.84 50 6904 72304 29495269
Failure to thrive 20.72 14.84 16 6938 7668 29559905
Cerebrovascular accident 20.04 14.84 51 6903 76860 29490713
Asthenia 19.58 14.84 101 6853 215149 29352424
Faecaloma 18.96 14.84 12 6942 4190 29563383
Gait inability 18.15 14.84 22 6932 18353 29549220
Blood pressure systolic increased 18.01 14.84 21 6933 16824 29550749
Nocturia 17.46 14.84 15 6939 8347 29559226
Incontinence 16.99 14.84 12 6942 5020 29562553
Rectal tenesmus 16.11 14.84 6 6948 652 29566921
Toxicity to various agents 15.47 14.84 11 6943 173650 29393923
Multiple sclerosis relapse 15.26 14.84 16 6938 11403 29556170
Dizziness 15.19 14.84 86 6868 189598 29377975
Muscular weakness 14.98 14.84 40 6914 62012 29505561

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis 97.56 11.29 68 22307 18873 64457484
Urinary tract infection 95.95 11.29 233 22142 231363 64244994
Sensitivity to weather change 87.67 11.29 44 22331 6670 64469687
Fall 74.73 11.29 314 22061 416512 64059845
Multiple sclerosis relapse 70.56 11.29 79 22296 41056 64435301
Urinary incontinence 68.21 11.29 73 22302 36078 64440279
Dry mouth 59.32 11.29 88 22287 60330 64416027
Pollakiuria 53.12 11.29 60 22315 31470 64444887
Lipoma 49.19 11.29 22 22353 2577 64473780
Cerebrovascular accident 46.15 11.29 128 22247 137455 64338902
Balance disorder 39.64 11.29 89 22286 83837 64392520
Seronegative arthritis 38.85 11.29 19 22356 2724 64473633
Micturition urgency 37.27 11.29 30 22345 10329 64466028
Bladder disorder 35.65 11.29 26 22349 7741 64468616
Toxicity to various agents 33.86 11.29 46 22329 363467 64112890
Urinary retention 33.81 11.29 61 22314 49140 64427217
Off label use 33.10 11.29 111 22264 632695 63843662
Prostatic specific antigen increased 30.73 11.29 25 22350 8735 64467622
Drug abuse 29.87 11.29 5 22370 132369 64343988
Dizziness 27.94 11.29 249 22126 429914 64046443
Stress urinary incontinence 25.46 11.29 12 22363 1586 64474771
Musculoskeletal discomfort 24.11 11.29 29 22346 16248 64460109
Incontinence 23.85 11.29 25 22350 12056 64464301
Hallucination, auditory 23.18 11.29 29 22346 16910 64459447
Maternal exposure during pregnancy 23.07 11.29 3 22372 95881 64380476
Bladder spasm 23.06 11.29 12 22363 1960 64474397
Secondary progressive multiple sclerosis 21.87 11.29 10 22365 1233 64475124
Febrile neutropenia 21.54 11.29 20 22355 187637 64288720
Inflammatory marker increased 21.34 11.29 20 22355 8431 64467926
Confusional state 20.58 11.29 158 22217 260986 64215371
Contraindicated product administered 20.45 11.29 6 22369 107823 64368534
Gait inability 20.07 11.29 45 22330 42323 64434034
Hypertonic bladder 19.32 11.29 13 22362 3405 64472952
Paranoia 19.27 11.29 26 22349 16326 64460031
Drug hypersensitivity 18.80 11.29 144 22231 237671 64238686
Asthenia 18.41 11.29 228 22147 427816 64048541
Gastrooesophageal reflux disease 18.35 11.29 67 22308 83076 64393281
Treatment failure 18.00 11.29 9 22366 116807 64359550
Transient ischaemic attack 17.75 11.29 44 22331 44138 64432219
Exposure during pregnancy 17.37 11.29 3 22372 77672 64398685
Systemic lupus erythematosus 17.35 11.29 3 22372 77609 64398748
Vision blurred 16.84 11.29 69 22306 90247 64386110
Nocturia 16.71 11.29 20 22355 11145 64465212
Mental status changes 15.85 11.29 52 22323 61110 64415247
Aphonia 15.41 11.29 17 22358 8680 64467677
Coronary artery disease 15.32 11.29 51 22324 60382 64415975
Neutrophil count decreased 15.19 11.29 4 22371 77192 64399165
Infusion related reaction 15.09 11.29 21 22354 164446 64311911
Body temperature fluctuation 15.04 11.29 11 22364 3287 64473070
Iliac artery occlusion 14.98 11.29 5 22370 265 64476092
Completed suicide 14.91 11.29 35 22340 224379 64251978
Urge incontinence 14.82 11.29 7 22368 929 64475428
Neutropenia 14.66 11.29 39 22336 239585 64236772
Product complaint 14.07 11.29 19 22356 11935 64464422
Blood pressure systolic increased 13.68 11.29 43 22332 49410 64426947
Cystitis 13.60 11.29 39 22336 42636 64433721
Drug intolerance 13.57 11.29 28 22347 187964 64288393
Bladder adenocarcinoma stage unspecified 13.30 11.29 3 22372 35 64476322
Speech disorder 13.29 11.29 42 22333 48399 64427958
Barrett's oesophagus 12.90 11.29 6 22369 769 64475588
Hand deformity 12.84 11.29 3 22372 62768 64413589
Multiple organ dysfunction syndrome 12.62 11.29 10 22365 101403 64374954
Escherichia urinary tract infection 12.48 11.29 18 22357 12019 64464338
Blood cholesterol increased 12.47 11.29 42 22333 50024 64426333
Psychotic disorder 12.40 11.29 33 22342 34545 64441812
Colitis ischaemic 12.39 11.29 19 22356 13395 64462962
Orthostatic hypotension 12.35 11.29 40 22335 46698 64429659
Dysphagia 12.25 11.29 71 22304 106741 64369616
Stomatitis 12.20 11.29 12 22363 109593 64366764
Body height decreased 12.08 11.29 14 22361 7540 64468817
Malignant neoplasm progression 11.84 11.29 13 22362 112858 64363499
Thrombocytopenia 11.82 11.29 39 22336 223762 64252595
Increased appetite 11.75 11.29 16 22359 10130 64466227
Death 11.73 11.29 109 22266 482596 63993761
Palpitations 11.69 11.29 69 22306 104419 64371938
Hyperlipidaemia 11.56 11.29 25 22350 22951 64453406
Oesophageal stenosis 11.51 11.29 10 22365 3824 64472533

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04BD07 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs for urinary frequency and incontinence
FDA MoA N0000000125 Cholinergic Muscarinic Antagonists
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D064804 Urological Agents
CHEBI has role CHEBI:48876 muscarinic antagonists
CHEBI has role CHEBI:51371 muscle relaxants
CHEBI has role CHEBI:53784 antispasmodics
FDA EPC N0000175700 Cholinergic Muscarinic Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Urgent desire to urinate indication 75088002
Urge incontinence of urine indication 87557004
Bladder muscle dysfunction - overactive indication 236633002
Increased Urinary Frequency indication
Torsades de pointes contraindication 31722008
Dementia contraindication 52448006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Myasthenia gravis contraindication 91637004 DOID:437
Prolonged QT interval contraindication 111975006
Bladder outflow obstruction contraindication 236645006
Pyloric obstruction contraindication 244815007
Retention of urine contraindication 267064002
Gastric retention contraindication 307227006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Gastrointestinal hypomotility contraindication 421807004
Poor metabolizer due to cytochrome p450 CYP2D6 variant contraindication 423629005
Congenital long QT syndrome contraindication 442917000
Aggravated Glaucoma contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.83 acidic
pKa2 9.14 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 8.49 CHEMBL CHEMBL
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Ki 8.57 CHEMBL CHEMBL
Muscarinic acetylcholine receptor M4 GPCR Ki 8.51 CHEMBL
Muscarinic acetylcholine receptor M5 GPCR Ki 8.66 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 7.77 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 8.85 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 8.16 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 8.85 CHEMBL
Muscarinic acetylcholine receptor M3 GPCR Ki 8.15 CHEMBL
Muscarinic acetylcholine receptor M5 GPCR Ki 8.66 CHEMBL
Muscarinic acetylcholine receptor M4 GPCR Ki 8.51 CHEMBL

External reference:

IDSource
4024113 VUID
N0000022118 NUI
D00646 KEGG_DRUG
124937-52-6 SECONDARY_CAS_RN
4021103 VANDF
4024113 VANDF
C0388753 UMLSCUI
CHEBI:9622 CHEBI
CHEMBL1382 ChEMBL_ID
DB01036 DRUGBANK_ID
CHEMBL1722209 ChEMBL_ID
D000068737 MESH_DESCRIPTOR_UI
443879 PUBCHEM_CID
360 IUPHAR_LIGAND_ID
6768 INN_ID
WHE7A56U7K UNII
119565 RXNORM
191519 MMSL
5600 MMSL
d04294 MMSL
007444 NDDF
007445 NDDF
109113000 SNOMEDCT_US
372570008 SNOMEDCT_US
386971005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Detrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-4541 TABLET, FILM COATED 1 mg ORAL NDA 25 sections
Detrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-4544 TABLET, FILM COATED 2 mg ORAL NDA 25 sections
Detrol LA HUMAN PRESCRIPTION DRUG LABEL 1 0009-5190 CAPSULE, EXTENDED RELEASE 2 mg ORAL NDA 29 sections
Detrol LA HUMAN PRESCRIPTION DRUG LABEL 1 0009-5191 CAPSULE, EXTENDED RELEASE 4 mg ORAL NDA 29 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0093-0010 TABLET, FILM COATED 1 mg ORAL ANDA 25 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0093-0018 TABLET, FILM COATED 2 mg ORAL ANDA 25 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7163 CAPSULE, EXTENDED RELEASE 2 mg ORAL ANDA 26 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7164 CAPSULE, EXTENDED RELEASE 4 mg ORAL ANDA 26 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 0904-6592 CAPSULE, EXTENDED RELEASE 2 mg ORAL ANDA 20 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 0904-6593 CAPSULE, EXTENDED RELEASE 4 mg ORAL ANDA 20 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 10135-706 TABLET, EXTENDED RELEASE 1 mg ORAL ANDA 22 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 10135-707 TABLET, EXTENDED RELEASE 2 mg ORAL ANDA 22 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 13668-189 CAPSULE, EXTENDED RELEASE 2 mg ORAL ANDA 20 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 13668-189 CAPSULE, EXTENDED RELEASE 2 mg ORAL ANDA 20 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 13668-190 CAPSULE, EXTENDED RELEASE 4 mg ORAL ANDA 20 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 13668-190 CAPSULE, EXTENDED RELEASE 4 mg ORAL ANDA 20 sections
Tolterodine Tartrate Human Prescription Drug Label 1 16571-126 TABLET, FILM COATED 1 mg ORAL ANDA 21 sections
Tolterodine Tartrate Human Prescription Drug Label 1 16571-127 TABLET, FILM COATED 2 mg ORAL ANDA 21 sections
DETROL HUMAN PRESCRIPTION DRUG LABEL 1 16590-959 TABLET, FILM COATED 2 mg ORAL NDA 23 sections
Tolterodine tartrate Human Prescription Drug Label 1 27241-191 CAPSULE, EXTENDED RELEASE 2 mg ORAL ANDA 26 sections
Tolterodine tartrate Human Prescription Drug Label 1 27241-192 CAPSULE, EXTENDED RELEASE 4 mg ORAL ANDA 26 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 29300-239 TABLET 1 mg ORAL ANDA 20 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 29300-240 TABLET 2 mg ORAL ANDA 20 sections
Tolterodine Tartrate Human Prescription Drug Label 1 31722-607 CAPSULE, EXTENDED RELEASE 2 mg ORAL ANDA 26 sections
Tolterodine Tartrate Human Prescription Drug Label 1 31722-608 CAPSULE, EXTENDED RELEASE 4 mg ORAL ANDA 26 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 31722-805 TABLET, FILM COATED 1 mg ORAL ANDA 22 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 31722-806 TABLET, FILM COATED 2 mg ORAL ANDA 22 sections
Tolterodine tartrate Human Prescription Drug Label 1 33342-097 TABLET, FILM COATED 1 mg ORAL ANDA 22 sections
Tolterodine tartrate Human Prescription Drug Label 1 33342-098 TABLET, FILM COATED 2 mg ORAL ANDA 22 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 43975-322 CAPSULE, EXTENDED RELEASE 2 mg ORAL ANDA 26 sections